Etanercept

Lilly wins EU approval for psoriatic arthritis mAb

30-Jan-2018 By Staff Reporter

Eli Lilly’s arthritis monoclonal antibody Taltz (ixekizumab) has been approved for a second indication in Europe.

Biogen looking to up its stake in Samsung biosimilar JV

26-Jan-2018 By Dan Stanton

Biogen has reported record biosimilar revenues and says it intends to increase its share in Samsung Bioepis.

GE wins another FlexFactory fit out in ‘big market’ China

24-Jan-2018 By Flora Southey

Clover Biopharmaceuticals will adopt GE Healthcare’s centrally automated FlexFactory platform at its facility in Zhejiang, China where it plans to make a biosimilar to Amgen’s Enbrel.

Room for another: Sandoz files Humira biosimilar in US

16-Jan-2018 By Dan Stanton

“There is room in most markets for a number of competitors” says Novartis as it submits its biosimilar adalimumab for review.

Six year wait for Humira biosimilar a win-win for Amgen and AbbVie, says lawyer

03-Oct-2017 By Dan Stanton

AbbVie’s settlement over the exclusivity of Humira creates a level of certainty for Amgen’s adalimumab biosimilars, according to a biotech lawyer.

Boehringer prepped to take on AbbVie and Amgen with US adalimumab biosimilar

29-Aug-2017 By Dan Stanton

The US FDA has approved its sixth biosimilar and second version of AbbVie’s best-selling monoclonal antibody Humira (adalimumab): Cyltezo, made by Boehringer-Ingelheim.

Samsung Bioepis ups EU presence with Humira biosimilar approval

25-Aug-2017 By Dan Stanton

Imraldi becomes the second version of AbbVie’s best-selling biologic Humira (adalimumab) to be approved and the fourth biosimilar success for Samsung Bioepis in Europe.

Samsung Bioepis teams with Takeda to take first steps into novel biologics space

22-Aug-2017 By Dan Stanton

Samsung Bioepis says it will continue focusing on biosimilars as it ventures into the innovative biologics space through a partnership with Takeda.

Second US infliximab biosimilar launched at 35% discount to J&J’s Remicade

25-Jul-2017 By Dan Stanton

Merck & Co. will challenge both reference drugmaker J&J and fellow biosimilar developer Pfizer through its version of Remicade, Renflexis.

Coherus terminates 51 jobs post FDA rejection

30-Jun-2017 By Flora Southey

Coherus Biosciences has submitted a US Securities and Exchange Commission filing, announcing it will eliminate 51 jobs to reduce operating costs.

EMA committee gives Samsung Bioepis nod for Humira biosimilar Imraldi

23-Jun-2017 By Dan Stanton

The EMA has recommended the approval of Samsung Bioepis’ adalimumab biosimilar, placing the firm on the brink of having three anti-TNF inhibitors in Europe.

Samsung Bioepis to take on J&J with FDA approved Remicade biosimilar

24-Apr-2017 By Dan Stanton

Samsung Bioepis’ Renflexis has become the second biosimilar of rheumatoid arthritis biologic Remicade (infliximab) to be recommended for approval in the US.